

Resource Summary Report

Generated by [NIF](#) on Sep 18, 2026

HuP-T3

RRID:CVCL_1299

Type: Cell Line

Proper Citation

RRID:CVCL_1299

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1299

Proper Citation: RRID:CVCL_1299

Description: Cell line HuP-T3 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Pancreatic adenocarcinoma

Defining Citation: [PMID:8454916](#), [PMID:11668190](#), [PMID:15126341](#), [PMID:15688027](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:25167228](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HuP-T3

Synonyms: HUP-T3, Hu-P-T3, HuPT3, HupT3, HUPT3

Cross References: BTO:BTO_0006547, CLO:CLO_0004299, CLO:CLO_0004300, EFO:EFO_0006596, CLDB:cl1769, CLDB:cl1770, CLDB:cl1771, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:640, BioSample:SAMN03472116, BioSample:SAMN10987811, cancercellines:CVCL_1299, Cell_Model_Passport:SIDM00533, ChEMBL-Cells:ChEMBL3308399, ChEMBL-Targets:ChEMBL1075477, Cosmic:907285, Cosmic:1995451, Cosmic:2434096, Cosmic-

CLP:907285, DepMap:ACH-000118, DSMZ:ACC-259, DSMZCellDive:ACC-259, ECACC:93121055, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:907285, GEO:GSM206515, GEO:GSM827205, GEO:GSM887151, GEO:GSM888223, GEO:GSM1374567, GEO:GSM1669922, IARC_TP53:21391, ICLC:HTL96006, LiGeA:CCLE_385, LINCS_LDP:LCL-1790, PharmacDB:HuPT3_644_2019, PRIDE:PXD030304, Progenetix:CVCL_1299, PubChem_Cell_line:CVCL_1299, Wikidata:Q54896894

ID: CVCL_1299

Record Creation Time: 20220427T220623+0000

Record Last Update: 20260913T004540+0000

Ratings and Alerts

No rating or validation information has been found for HuP-T3.

No alerts have been found for HuP-T3.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Murr J, et al. (2026) The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. MedComm, 7(6), e70794.

Kamgar M, et al. (2026) Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma. Cancer research, 86(8), 2042.

Burge RA, et al. (2026) KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. Cancer research, 86(8), 1868.

Wang S, et al. (2025) IFN- γ -driven UBE2D3 upregulation impairs antigen presentation pathways and anti-tumor immunity in pancreatic cancer. Nature communications, 16(1), 10733.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.

Hagel KR, et al. (2023) Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer. *Cancer research*, 83(4), 613.

Lier S, et al. (2022) A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer. *Bioorganic chemistry*, 119, 105505.

Banh RS, et al. (2020) Neurons Release Serine to Support mRNA Translation in Pancreatic Cancer. *Cell*, 183(5), 1202.

Neggers JE, et al. (2020) Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. *Cell reports*, 33(11), 108493.

Nicolay BN, et al. (2013) Loss of RBF1 changes glutamine catabolism. *Genes & development*, 27(2), 182.